Study of Antibacterial Antibodies in Adults with Pulmonary Cystic Fibrosis

What this Trial Is About

Researchers are studying patients with pulmonary cystic fibrosis CF, focusing on those who have or have had lung colonization or infections by bacteria like Pseudomonas aeruginosa or Staphylococcus aureus. The study aims to detect antibodies in the blood that can neutralize bacterial virulence factors, which play a key role in infection and tissue damage. By analyzing these antibodies and related B cells, researchers hope to develop specialized monoclonal antibodies that can better target these harmful factors. Participants include those with CF, whether or not they currently have bacterial colonization, as well as healthy people matched by age and sex, including some with acute or chronic bacterial infections. The study involves blood sampling, starting with 15 ml of whole blood for screening, and up to 400 ml for B cell isolation. Blood collection is done carefully considering total blood volume based on body weight and sex. During the study, participants will have blood drawn to analyze the presence and function of antibacterial antibodies. Researchers will monitor vital signs like blood pressure, oxygen levels, heart rate, and temperature to ensure safety. The main outcome is to measure how common these antibacterial antibodies are over three years. Participation involves blood tests and health monitoring, with study activities designed to safely collect the information needed to understand antibody responses in CF.

Characterization of Antibacterial Antibodies in Patients With Cystic Fibrosis